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PLK4 is a serine/threonine kinase known to be involved in cell cycle regulation 
and centrosome duplication. Its protein levels are tightly regulated in order to prevent 
centrosome irregularities that would lead to aneuploidy and eventual oncogenesis. 
Previous studies have shown that PLK4 is under epigenetic control and could also be 
involved in regulating epigenetic mechanisms. In this study, centrinone-B (a PLK4 
inhibitor) was used to determine the functional mechanisms of PLK4 in epigenetic 
regulation. We determined that centrinone-B was able to change the localization patterns 
of de-novo methyltransferases DNMT3a and DNMT3b in mouse fibroblasts but did not 
change their overall protein levels. Furthermore, application of centrinone-B could affect 
global methylation levels in the same cells, which we speculate is due to the localization 
changes. Although we could not observe a direct kinase interaction between PLK4 and 
DNMT3a, these findings suggest that PLK4 may regulate epigenetic mechanisms by 
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Polo-like Kinase Family Overview 
The polo-like kinases (collectively, PLKs) are a family of serine-threonine kinases that have 
important roles in cell cycle regulation and centrosome duplication. They were first discovered in D. 
melanogaster as the gene polo, named after an abnormal spindle pole phenotype [1]. Since then, they 
have been identified in a wide range of organisms including S. cerevisiae (Cdc5), X. laevis (Plx), and C. 
elegans (Zyg-1), highlighting their conservation across species and importance in mitotic pathways [2]. In 
mammals, there are five known members (PLK1-5) that are each uniquely regulated with separate 
functions in mitosis.  
PLK1 is the best-characterized member of the family with roles primarily centralized in mitosis. 
It localizes to multiple structures during mitosis and has been shown to be required for proper cell 
division. During late G2, PLK1 localizes to the centrosomes and regulates mitotic entry by 
phosphorylating CDC25C, which allows nuclear translocation of CDC25C and subsequent 
dephosphorylation of cyclin B-bound CDK1 [3,4]. It has also been shown to regulate nuclear envelope 
breakdown during prophase by phosphorylating p150glued-dynactin complexes [5]. PLK1 also negatively 
regulates PCR1 (protein regulator of cytokinesis) in order to prevent premature cytokinesis [6]. 
Overexpression of PLK1 increases cellular susceptibility to cancer formation through aberrant mitosis and 
increased sensitivity to IR and UV radiation [7]. This is due to the decreased functionality of the DNA 
damage response pathway; proteins such as ATM and Chk2 were suppressed [7]. Coincidentally, 
upregulation of PLK1 is also commonly found in a wide-range of cancers [8].  
PLK2 is predominantly known for its interaction with DNA damage response proteins and 
involvement in cell cycle regulation. PLK2 mRNA levels are upregulated in response to cellular stress 
and it has been shown to directly interact with CHK1, CHK2, and p53 through in vitro binding assays [9]. 




process by promoting procentriole formation [10]. Cells deficient in PLK2 have been shown to be 
susceptible to genotoxic stresses and have increased frequencies apoptosis, which indicate potential tumor 
suppressive roles [11]. Respectively, PLK2 is also predominantly transcriptionally silenced in B-cell 
malignancies [12].  
Similar to PLK2, PLK3 is most known for its activities in the DNA damage response pathway 
and its tumor suppressive roles. Studies have shown that PLK3 acts downstream of Chk2 and 
phosphorylates p53 at Ser20 after ionizing radiation treatments which leads to increased expression of 
p21 [13,14]. PLK3 is also responsible for phosphorylating and stabilizing tumor suppressor PTEN under 
hypoxia, which negatively regulates the AKT1 pathway for cell growth and proliferation [15]. 
Investigations into aged PLK3 null mice reveal weight gain and tumor formation in multiple organs [16]. 
Furthermore, downregulation of PLK3 expression has been reported in multiple cancers including lung 
and ovary, suggesting that lower levels of PLK3 are associated with tumor development [17,18]. 
PLK4 is known mainly for centrosome regulation but has other roles in mitotic progression and 
ciliogenesis [19]. PLK4 directly phosphorylates centrosome proteins CEP152 and CEP192 at the centriole 
base, which is required for centriole duplication [20,21]. The localization of Ect2 to the cleavage furrow 
for the completion of cytokinesis is also dependent on PLK4 phosphorylation [22]. Studies investigating 
primary cilia formation have found that PLK4 plays a major role in the formation of new cilium. 
Dysregulation of PLK4 in this context reduces the total number of cilia in keratinocytes and contributes to 
defective cilium function, which indicates that PLK4 may be a biomarker for ciliary dyskinesia 
[19,23,24]. 
PLK5 is the newest member of the family, as such, not much is known about it. Unlike the other 
PLKs, PLK5 has a truncated kinase domain but still retains some phosphorylating function [25]. It has 
been implicated in the DNA damage response much like PLK3 and PLK2. PLK5 mRNA is upregulated in 
response to DNA damage and microtubule disruption, suggesting that it is a stress-induced protein 
involved in maintaining genomic stability. Furthermore, overexpression of PLK5 in HEK293 or NIH/3T3 




inhibit axon growth and neurite formation, which may suggest that it is involved in neurodevelopment. 
Interestingly, PLK5 is transcriptionally silenced by promoter methylation in glioblastomas and 
astrocytomas [25]. 
PLK4 Structure 
The mammalian PLK family members likely all diverged from an ancestral PLK1-like protein. 
Each member shares a conserved catalytic N-terminal kinase domain (PLK5 kinase domain is truncated), 
which is responsible for phosphorylating protein substrates. The non-catalytic C-terminal end contains a 
polo-box domain (PBD) that is unique to the PLKs (Figure 1). The polo-box domain consists of two 
highly conserved polo-box (PB) motifs of about 70-80 amino acids each and a linker region between 
them. It regulates subcellular localization of the protein, substrate binding and autoinhibition of the kinase 
domain [27].  
PLK4 is the most divergent member of the family. It possesses a kinase domain as well, however, 
unlike the kinase domain of PLK1, it has a unique phosphorylation motif. This may imply that it can 
target a wider range of substrates [28]. Also, PLK4 contains 3 polo-box motifs instead of the usual 2 
found in PLK1-3. PB1 and PB2 act as one unit and mediate the homodimerization of PLK4 and also its 
interaction with Asl (Asterless/CEP152) [29]. PB3 is required for PLK4 binding to STIL, which leads 
stabilization at the centriole and is a crucial step for centriole duplication [30]. When all three Polo-boxes 
are removed PLK4 loses its capability to localize to the centrosome [29].  
There are three PEST sequences within PLK4 that regulate stability and turnover rate of the 
kinase [31]. The first PEST sequence contains a degron motif that becomes a binding site for SCF 
(Skp1/cullin/F-box) when phosphorylated. Upon binding, SCF ubiquitinates PLK4 and signals it for 
proteasomal degradation. Mutation of the degron motif to prevent phosphorylation increases the stability 
of PLK4 and leads to increased activity of wild-type PLK4 [32]. Phosphorylation of the degron motif is 




mechanism, PLK4 is able to regulate its own destruction, which is a crucial factor in tightly regulating 



























Figure 1: Polo-like Kinase Protein Structure and Domains 
A representation of the conserved domains and motifs that are unique to the PLK family. All PLK family 
members share a common protein structure: N-terminal kinase domains (KD) and C-terminal Polo-box 
motifs (PB). PLK4 uniquely has 3 Polo-box motifs that regulate substrate binding and subcellular 





























Centriole Biogenesis / Centriole Duplication 
PLK4 is most known for regulating proper centriole duplication and centrosome number during 
cell division [34]. Centrosomes in mammalian cells act as microtubule organizing centers (MTOC), 
which are a major site for microtubule nucleation and localization. Proper organization of mitotic/meiotic 
spindles is necessary for the even distribution of chromosomes during cell division [35]. Centrosomes 
consist of two centrioles that are orthogonally arranged at their base (proximal end) and are surrounded by 
a protein matrix collectively named pericentriolar material (PCM). The PCM is a dynamic collection of 
proteins that include CEP192, CEP152, y-tubulin and many others which are required for the nucleation 
of new microtubules [36].  
Centriole biogenesis occurs once per cell cycle and begins during the G1 phase. After mitosis, 
mother and daughter centrioles disengage through the regulation of PLK1 and Separase to allow 
formation of procentrioles on the proximal ends [37]. At the S phase transition, PLK4 is recruited to the 
centrosome by PCM components CEP152 and CEP192. Phosphorylation of CEP152 and other PCM 
components by PLK4 initiates centriole biogenesis. During S phase, STIL, SAS6 and CPAP are recruited 
to the procentriole location to form a cartwheel base where microtubules will dimerize and elongate to 
form a daughter centriole [38]. PLK4 is degraded by SCF during elongation to prevent centriole 
reduplication at other sites along the mother centriole. After duplication, both centrosomes recruit 
additional PCM and separate to form two mature centrosomes by the end of G2. These two centrosomes 
will act as MTOCs to preserve cellular polarity during mitosis [39]. 
The overall protein levels of PLK4 need to be tightly regulated in order to prevent centrosomal 
and mitotic abnormalities. Overexpression of PLK4 has been found to induce centriole amplification and 
de novo centrosome formation in drosophila [40]. Depletion of PLK4 inhibits centriole duplication and 
has been linked to cytokinesis failure [41]. Both overexpression and depletion of PLK4 lead to spindle 




Cell Cycle Regulation 
In addition to regulating centriole duplication, PLK4 has also been implicated in other cellular 
response pathways. Chk2 is a key protein involved in the DNA-damage signaling pathway. It plays a 
critical role in stabilizing p53 to induce cell cycle arrest or promote apoptosis in response to ionizing or 
UV radiation [43]. In-vitro kinase assays have shown that Chk2 is a PLK4 substrate, which suggests that 
PLK4 may be involved in maintaining genomic stability [44]. Furthermore, PLK4 has been shown to 
interact with p53 through its third Polo-box, however, the functional significance of this interaction is not 
understood [45]. Li et al. has suggested that PLK4 may be negatively regulated by p53 at a transcriptional 
level by recruitment of a histone deacetylase (HDAC) complex to the PLK4 promoter [46]. In the context 
of genotoxic stress, this response is needed to inhibit cell cycle progression to activate the DNA repair or 
apoptotic pathways. PLK4 could trigger a negative feedback loop where it phosphorylates Chk2 in order 
to stabilize p53 and ultimately repress itself. This model is supported by the observations of heterozygous 
PLK4 embryonic fibroblasts (PLK4+/- MEFs) that have a reduced p53 response under oxidative stress 
[47]. 
PLK4 is also involved in the progression of the cell cycle through its interactions with Cdc25C 
and Ect2. CDC25C is a phosphatase and plays a key role in mitotic entry. It is required to 
dephosphorylate Cyclin B-bound CKD1 to trigger entry into mitosis. CDC25C has been shown to localize 
to the centrosome and be a direct substrate of PLK4 [48]. The phosphorylation event has not been fully 
characterized but it is speculated that it could be involved in the nuclear localization of CDC25C. PLK1 
and PLK3 are also shown to phosphorylate CDC25C and contribute to its nuclear accumulation; this 
suggests that PLK4 may have a similar overlapping role with the other PLK family members [49,50]. 
Furthermore, reciprocal co-immunoprecipitation and kinase assays have shown physical interactions 
between PLK4 and Ect2 [21]. Ect2 is a protein required for cytokinesis and its localization to the cleavage 
furrow during anaphase has been shown to be PLK4 dependent. PLK4+/- MEFs frequently fail to complete 









Figure 2: The Centrosome Cycle 
An illustration that demonstrates the process of centriole duplication during different phases of the cell 
cycle. (1) Mother and daughter centrioles disengage in early G1 through the activity of PLK1 and 
Separase. (2) PLK4 is recruited to the centriole base in late G1 and initiates procentriole formation with 
multiple interacting partners. (3) The procentriole elongates through the stabilization of alpha and beta 
tubulin dimers and completes at the end of the S-phase. (4) Two fully mature centrosomes form at G2 and 
separate to act as microtubule organizing centers (MTOC) during mitosis. (Figure adapted and modified 

























PLK4 Mouse Model 
PLK4 loss of function studies in mice has revealed that it is an essential protein for proper embryonic 
development. PLK4-null mice are embryonic lethal at day E7.5 after gastrulation due to late mitotic 
failure. These embryos displayed an increase in Cyclin-B1 positive cells in the late states of anaphase 
suggesting that PLK4 is needed for degradation of Cyclin-B1 and successive mitotic exit [51].  
  Interestingly, PLK4 heterozygous mice develop normally and are viable despite having only one 
functioning allele. However, elderly PLK4+/- mice had a greater incidence of liver and lung cancers 
compared to their wild-type littermates, which indicates a haploinsufficient effect for tumor suppression 
[52]. Partial hepatectomy of PLK4+/- mice displayed tissue disorganization and spindle abnormalities due 
to mitotic defects associated with p53 and p21 suppression [51]. 
  Studies investigating PLK4+/- embryonic fibroblasts have shown cellular irregularities and 
abnormal gene expression patterns. PLK4+/- MEFs have an increased incidence of uneven chromosome 
segregation and overall aneuploidy when compared to wild-type cells. This seems to be a consequence of 
an increased number of observed MTOCs during interphase [52]. Western-blot data has shown PLK4+/- 
MEFs to have higher protein levels of p53, p21 and Chk2 when compared to wild-type cells which 
indicates genomic instability that is consistent with PLK4’s proposed role in the DNA damage response 
[53]. 
Tumorigenesis 
A review of PLK4’s substrates and its involvement in the centrosome cycle provide an attractive 
explanation for PLK4’s role in cancer formation. Theodor Boveri first proposed that centrosome 
amplification (CA) could be involved in generating cell malignancy by promoting chromosomal 
instability (CIN) and subsequent aneuploidy [54]. PLK4 overexpression is consistently used as a method 
to study centrosome amplification as well as the long-term consequences of cells having extra 
centrosomes [22,55]. For example, it has been reported that PLK4-overexpressing neural cells with 




PLK4-overexpression in epithelial cells was found to disrupt cell-cell adhesion and promote malignant 
invasion [57]. Therefore, it is fitting that PLK4 is shown to be upregulated in a wide range of cancers 
such as gastric, breast and glioblastomas and that it is associated with poor prognostic outcomes 
[58,59,60]. 
  Contrarily, in hepatocellular carcinoma (HCC) tissues, PLK4 levels were recurrently down-
regulated [61]. Multiple HCC cell lines showed the same decrease in PLK4 expression and researchers 
determined that larger tumors were overall correlated with lower expression of PLK4. Furthermore, HCC 
patients with low PLK4 expression overall had a worse prognosis than those with higher levels of PLK4, 
which suggests that it may be a predictor for overall survival [61]. These findings may indicate dual roles 
for PLK4; it acts oncogenic in overexpressed conditions and as a tumor suppressor in haploinsufficient 
conditions. 
  Centrosome amplification has been reported in nearly all types of human cancer; however, there 
is some debate on whether it can be a true driver of tumorigenesis [62,63,64]. Studies in mice revealed 
that PLK4-induced centrosome amplification in epidermal cells caused spindle errors and chromosome 
segregation defects but failed to promote cell proliferation and carcinogenesis [65]. Additionally, 
centrosome amplification failed to enhance the growth of chemically induced skin tumors and did not 
cause spontaneous tumor formation in aging mice [66]. Other studies have found that centrosome 
amplification can accelerate tumorigenesis only in p53-deficient epidermal cells suggesting that 
supernumerary centrosomes are insufficient to drive tumor formation [67]. In contrast, Levine et al. 
demonstrated that centrosome amplification and aneuploidy in vivo could induce spontaneous formation 
of lymphomas and sarcomas in the presence of wild-type p53 [68]. Their mouse model drove 
overexpression of PLK4 at a low level that only led to the creation of one or two extra centrosomes per 
cell. This is similar to centrosome amplification found in human tumors [69]. Taken together, these 







Epigenetics refers to the study of heritable changes in gene function that do not involve changes 
in DNA sequence [70]. These changes in gene function are due to the altered expression of genes through 
modified chromatin packaging. Over the past decade, a growing number of studies have shown how 
chronic exposure to environmental stresses and toxicants can promote tumorigenesis through epigenetic 
mechanisms [71,72]. Change of gene expression patterns in critical tumor suppressor or oncogenic genes 
through DNA methylation or histone modifications will increase the likelihood of carcinogenesis. 
Luckily, epigenetic modifications are not permanent and many drugs exist today that specifically target 
epigenetic regulators [73]. 
DNA Methylation 
One of the most extensively studied epigenetic mechanisms is cytosine methylation [74]. The 
fifth-carbon of a cytosine nucleotide can become methylated into 5-methylcytosine (5mC), which 
interferes with transcription factor binding and prevents gene expression. Methylated cytosines are 
primarily found on CpG dinucleotides and long stretches of DNA that contain greater proportions of CpG 
sites are known as CpG islands [75]. About 70% of human gene promoters contain CpG islands and 
hypermethylation of these areas is associated with transcriptional silencing [76,77]. 
  The DNA-methyltransferase family of proteins are the enzymes that catalyze the methyl groups 
onto cytosine residues using S-adenosylmethionine (SAM) as the methyl donor [78]. There are five 
known members of the DNMT family but only DNMT1, DNMT3a and DNMT3b are known to 
contribute to the global patterns of DNA methylation. DNMT1 is the maintenance protein and is involved 
in the methylation of cytosine residues in newly synthesized daughter DNA strands to match the 
methylation patterns of the parental strands [79]. DNMT3a and DNMT3b are classified as de novo 





In the nucleus, genomic DNA is packaged into nucleosome subunits that condense into 
chromatin. Each nucleosome consists of DNA wrapped around 4 core histone proteins (H2A, H2B, H3, 
H4) and additional linker DNA stabilized by histone protein H1 [81]. Consecutive nucleosome subunits 
have been described as “beads-on-a-string” and can be categorized into two types of chromatin defined by 
their level of compaction. Euchromatin is loosely packed chromatin and typically represents 
transcriptionally active genetic regions. Heterochromatin is tightly packed chromatin and generally 
represents silenced genetic regions. 
  Chromatin conformation is dynamic and can switch to an active or inactive state by chemical 
modifications of histones. Histone methylation occurs on both arginine and lysine residues on the tails of 
histone proteins H3 and H4 [82]. Unlike DNA methylation, histone methylation is associated with both 
gene repression and activation. The H3K27me3 mark (tri-methylation of the 4th lysine residue of histone 
H3) is associated with transcriptional repression while the H3K4me2 mark is associated with 
transcriptional activation [83,84]. Furthermore, lysine residues on histone tails can also be modified by 
acetylation and is strongly associated with transcriptional activation. Histone acetyltransferase proteins 
(HATs) catalyze the addition of acetyl groups to lysine using coenzyme A as a cofactor and induce an 
open chromatin state, whereas histone deacetylase proteins (HDACs) remove acetyl groups and induce a 
closed chromatin state. Together, methylation and acetylation of histone tails play a key role in 
















Figure 3: Epigenetic Modifications of DNA and Histones 
(A) DNA hypermethylation of gene promoters by DNA-methyltransferase proteins (DNMT) can silence 
gene expression by inhibiting transcription factor binding. Cytosine methylation marks can be reversed by 
TET2 enzymes. (B) Lysine and Arginine residues on histone tails can be modified by histone 
acetyltransferase (HAT) or histone methyltransferase (HMT) enzymes. These marks are dynamic and can 
be reversed by histone deacetylase (HDAC) and histone demethylase (HDM) enzymes.  (Figure adapted 


























Global loss of DNA methylation was the first epigenetic change described in cancer. Feinberg 
and Vogelstein originally revealed that tumor tissues had a lower proportion of methylated cytosines 
when compared with normal tissues [85]. Later, studies using high-performance liquid chromatography 
confirmed that 5mC content was inversely associated with tumor progression [86]. Global 
hypomethylation of DNA is typically seen in intergenic repetitive regions of the genome and is correlated 
with elevated instability. Tandem repeats near centromeric DNA are required to keep DNA tightly packed 
into a heterochromatic state. Hypomethylation of these areas can lead to chromatin decondensation and 
the amplification of chromosome rearrangements and translocation events [87]. Frequent unbalanced 
translocation events increase the potential for disruptive gene deletions or carcinogenic chromosome 
fusions, for example, the Philadelphia chromosome found in leukemia [88]. Additionally, researchers 
have found that deleting DNMT1 in murine embryonic stem cells, which caused global hypomethylation, 
increased the incidence at which translocation events would occur [89].  
  Hypomethylation of normally silenced gene regions can contribute to tumorigenesis as well. 
Long interspersed elements (LINE-1) are retrotransposons that make up about 17% of the human genome 
[90]. In normal tissues these sequences are silenced by methylation but hypomethylation of these 
elements have been implicated in tumorigenesis. Activation of these retrotransposons can cause random 
insertional mutations or large gene inversions that can disrupt normal patterns of gene expression [91]. 
Hypomethylation of LINE-1 elements are regularly found in colorectal and hepatocellular cancers and 
play a key role in the formation of lung neoplasias [92,93,94]. Additionally, hypomethylation of 
imprinted regions can cause aberrant gene expression. Imprinted genes are normally mono-allelically 
expressed but reactivation of promoter regions in these genes lead to expression of both maternal and 
paternal alleles. Aberrant biallelic expression of IGF2 and H19 has been shown to be a significant risk 
factor for human colorectal cancer [94]. 
In contrast with hypomethylation of intergenic regions, hypermethylation of CpG islands can 




tissues are typically unmethylated. However, hypermethylation of these sites is often an early event in 
cancer formation [95]. Tumor suppressor genes such as PTEN, a protein that inhibits proliferation, and 
p16, a cell-cycle regulator, are often found to be hypermethylated in multiple human cancers [96,97]. 
Inactivation of tumor suppressors directly promotes carcinogenesis due to lack of cell cycle controls. 
Hypermethylation of transcription factors can also indirectly lead to tumorigenesis due to the 
uncontrollable downstream effects. GATA-4 and GATA-5 are transcription factors that are essential for 
development and differentiation of the gastrointestinal tract and both inactivated by promoter 
hypermethylation in colorectal cancers [98]. 
  Furthermore, dysregulation of epigenetic modifying proteins is also associated with 
tumorigenesis. Overexpression of DNMT1/3a/3b is all commonly found in tumors and is speculated to be 
the cause of hypermethylation in CpG islands [99,100]. Mutations in TET2, a protein that catalyzes the 
first step of cytosine demethylation, have been observed in numerous hematological malignancies and is 
associated with poor prognosis in AML [101]. EZH2, a histone-lysine-methyltransferase, is 
overexpressed in prostate cancer and is linked to progressive malignancy [102]. Additionally, recurrent 
DNMT3a loss-of-function mutations have also been reported in acute myelogenous leukemia [103]. Both 
overexpression and downregulation of epigenetic modifiers have a strong association with progressive 
cancer formation and poor patient prognosis.  
 
 
Epigenetics of the Polo-like Kinases 
Multiple members of the polo-like kinase family are epigenetically dysregulated in cancer. Ward 
and Hudson observed the CpG promoter of PLK1 to be methylated in normal human bone marrow 
aspirates [47]. However, when observing the aspirates of various blood neoplasms (B-cell lymphomas, 
MDS and leukemias), the PLK1 promoter was hypomethylated, which corresponded with an increase in 




both unmethylated in normal bone marrow tissue but hypermethylated in neoplastic tissues. Similar 
findings were noted when investigating the promoter methylation status of the PLKs in cell lines derived 
from blood neoplasms [104]. This signifies opposing roles for the PLKs in hematological malignancies: 
PLK1 acting as an oncogene and PLK2/3 having tumor suppressive functions. Identical promoter 
methylation statuses for the PLKs have also been reported in human HCC cell lines [105]. These 
epigenetic studies are consistent with the overall literature in that PLK1 is regularly overexpressed in a 
multitude of malignant tissues and PLK2/3 are commonly suppressed [106,107,108].  
  The promoter of PLK4 is similarly observed to be epigenetically dysregulated in different human 
cancer types. In bone marrow aspirates of hematological neoplasms, PLK4 is hypermethylated, which 
also coincides with a decrease in PLK4 protein level. It is speculated that PLK4 levels may also be 
tethered to genetic biomarkers of hematological malignancies such as JAK2 because their expression is 
inversely correlated [104]. The PLK4 promoter is also hypermethylated in the liver tissues of aged PLK4+/- 
mice and it directly contributes to further deteriorated transcript levels, however, this effect is not as 
common with WT mice [104,109]. It seems that PLK4+/- mice are more susceptible to promoter 
hypermethylation and loss of PLK4 expression as aging occurs. Ward and Hudson observed that PLK4+/- 
MEFs under exposure to alcohol and hypoxia are more prone to promoter methylation when compared to 
WT MEFs [109,47]. This suggests that DNA methylation regulators in response to cellular stress may 
target the PLK4 promoter. Interestingly, there are some gender imbalances PLK4+/- mice; the PLK4 
promoter is regularly methylated in the livers of male mice [109]. This coincides with the observation that 
PLK4+/- male mice are more likely to develop liver tumors than their female counterparts. Furthermore, 
DNMT3a protein levels are increased in PLK4+/- MEF under hypoxia and H202 treatment and global 
methylation levels in these cells are increased as well [47]. This result may imply a possible relationship 








PLK4 is mainly known for cell cycle regulation and centrosome duplication, however, recent 
publications by Ward and Hudson point to a possible relationship between DNMT3a and PLK4 [47]. This 
study is aimed to elucidate the role of PLK4 in epigenetic regulation and its potential partnership with 
DNMT3a as a substrate.  
New therapeutic drugs aimed to target PLK4 specifically have been synthesized for possible 
chemotherapy. Centrinone-B is a unique drug that has shown high affinity and efficacy for PLK4 
inhibition in vivo [110]. It specifically binds to the kinase domain of PLK4 and hinders its transition to an 
active state by forming hydrophobic contacts with PLK4’s activating DFG (Asp-Phe-Gly) motif [110]. 
Wong et al. has used centrinone-B to study the effects of prolonged centriole depletion. Treatment with 
centrinone-B will allow insight into the phenotypic cellular effects of PLK4 inhibition in regards to global 
















Materials and Methods 
Cell Culture 
NIH/3T3 cells were cultured in Dulbecco’s Modified Eagle’s Media (DMEM) supplemented with 10% 
fetal bovine serum (FBS). Murine embryonic fibroblasts (MEF) derived from PLK4+/- mice were cultured 
in DMEM supplemented with 20% FBS, 1% penicillin/streptomycin, 0.5% gentamicin and amphotericin 
B. HEK293T cells were cultured in DMEM supplemented with 10% FBS. All cells were maintained at 
37°C with 5% CO2. 
  
Immunocytochemistry/Immunofluorescence 
NIH/3T3 and MEF cells were grown on glass slides in 6-well plates at 60-80% confluence. NIH/3T3 cells 
were treated with DMSO or 300nM of centrinone-B for 16-20 Hours overnight. Cells were fixed with 
3.7% PFA +0.1% triton X-100 and incubated with DNMT3a antibody (Sigma-Aldrich), DNMT3b 
antibody (Santa-cruz), or DNMT1 antibody (Cell-Signalling) at a 1:100 dilution for 16 hours at 4°C. 
Secondary antibody Alexa Fluor 568 anti-rabbit (Invitrogen)  was incubated at room temperature in a 
1:500 dilution for 1 hour. Cells were then stained with Hoechst 33342 at a dilution of 1:10000 for 2 
minutes at room temperature. Fluorescent images were taken using Northern Eclipse software. 
  
Transient Transfections 
Transient transfections of NIH/3T3 cells were performed with 1mg/ml of PEI (polyethylenimine-
branched, Sigma-Aldrich) with 20g of purified plasmid DNA (PLK4 ShRNA) and supplemented with 




Transient transfections of HEK293T cells were performed with 1mg/ml of PEI with 10mg of purified 
plasmid DNA (Flag-PLK4 constructs). Cells were incubated with transfection reagents for 18-24 hours. 
  
Flow Cytometry 
NIH/3T3 cells were treated with DMSO, 300nM of centrinone-B or Nocodazole for 18 hours. Treated 
cells were collected and fixed in ice cold 80% ethanol for 1 hour. They were then washed in PBS and 
resuspended in a PBS solution supplemented with 0.5M EDTA and 0.1% Triton-X. Samples were 
incubated with propidium iodide overnight and cell cycle analysis was performed on a cytomic FC 500 
flow cytometer.  
  
Western Blot 
Whole cell protein was extracted using a lysis buffer (50mM Tris-Cl, 150mM NaCl, 1% Triton-X, 0.1% 
SDS supplemented with protease inhibitor). 20ug of total protein was used for Western Blot analysis. 
Primary antibodies DNMT3a, DNMT3b, DNMT1, PLK4, and GAPDH were used. Secondary antibodies 
anti-rabbit HRP and anti-mouse HRP were used. Bands were visualized with ECL reagent (Thermo-
fisher) and images obtained from ProteinSimple Fluorchem E system. Densitometry analysis was 
performed using ImageJ software.  
  
Expression and Purification of GST-Fusion Protein 
GST-DNMT3a (Cloned by Lana El-Osta) was expressed in BL21 cells by induction with 1mM of IPTG 
(isopropyl-B-D-1-thiogalactopyranoside at 28°C for 4 hours. Bacterial pellets were lysed with a cell lysis 
buffer (50 mM Tris-HCl pH7.5, 100 mM NaCl, 0.1 mM EDTA, 0.1% Triton X-100, 2 mM DTT, and 
protease inhibitor pellet) and sonicated. After centrifugation at 13000 rpm for 30 mins, the supernatant 




washed with a cell lysis buffer and 2 times with a wash buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 
mM DTT). Soluble fusion protein was then eluted from the column with an elution buffer (50mM Tris 
HCl pH 7.5, 100 mM NaCl, 10 mM glutathione). Following purification, the eluted protein was 
concentrated using an Amicon Ultra centrifugal filter.  
  
Invitro Kinase Assay 
After 48 hour transfections, cells were lysed and whole cell lysate was collected and incubated with 1ug 
of anti-flag antibody (Sigma) for 1 hour at 4°C. The lysate was then incubated with 20ul of calibrated 
Protein-G Sepharose (GE Healthcare Life Sciences) beads for 1 hour at 4°C. Immune Complexes were 
washed twice with a wash buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl,0.1% Triton X-100), twice 
with a second wash buffer supplemented with 500mM LiCl and once with a kinase buffer (60 mM Hepes 
pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 50 mM NaF,25 mM dithiothreitol, 125 µM cold ATP and Roche 
protease inhibitor pellet). Bacterial purified GST-DNMT3a was incubated with purified immune 
complexes of Flag-PLK4 constructs. For each kinase reaction, 10ug of GST-DNMT3a and 10 µCi of [γ-
32P] [Perkin Elmer] were supplemented to the kinase buffer. Kinase reactions incubated at 30°C for 30 
mins. Protein samples were resolved through an SDS-PAGE and blotted onto PVDF membrane and 
subjected to autoradiography. Radioactive bands were visualized using Cyclone Plus Phosphor Imager 
(Perkin Elmer) and Optiquant software. 
 
Endogenous Coimmunoprecipitation 
15ul per plate of protein-G sepharose beads were washed twice using a wash buffer (50mM Tris-Cl 
pH7.4, 150mM NaCl, and 0.025% Triton-X) and equilibrated with a lysis buffer (50mM Tris-Cl, 150mM 
NaCl, 1% Triton-X, 0.1% SDS). Whole cell lysates were incubated with anti-PLK4 antibody for 1 hour at 
4°C. The lysates were then incubated with the equilibrated beads for 1 hour at 4°C. Immune Complexes 





Global Methylation Assay 
Genomic DNA was collected from cellular pellets using phenol/chloroform extraction. Genomic DNA 
from samples were subjected to global methylation analysis using the MethylFlash Global DNA 
Methylation quantification kit (Epigentek). Experiments were carried out according to manufacturer’s 
recommendations using 100 ng of DNA. Colorimetric analysis was carried out on a Perkin Elmer Wallac 
Victor3 1420 Multilabel Counter. 
 
Perinuclear Cell Counts 
NIH/3T3 cells were grown on glass slides in 6-well plates at 60-80% confluence. NIH/3T3 cells were 
transfected with a Flag-PLK4 or Flag-G95L plasmid and the next day treated with 300nM of centrinone-
B for 16-20 Hours overnight. Cells were fixed with 3.7% PFA +0.1% triton X-100 and incubated with 
DNMT3a antibody (Sigma-Aldrich) at a 1:100 dilution for 16 hours at 4°C. Secondary antibody Alexa 
Fluor 568 anti-rabbit (Invitrogen)  was incubated at room temperature in a 1:500 dilution for 1 hour. Cells 
were then stained with Hoechst 33342 at a dilution of 1:10000 for 2 minutes at room temperature. Slides 
were observed under UV and >200 cells were manually counted to calculate the proportion of perinuclear 















PLK4 interaction with DNMT3a 
Ward and Hudson pointed to a possible substrate relationship between PLK4 and DNMT3a [47]. 
As an initial step towards understanding this relationship, a co-immunoprecipitation was performed to 
determine if a physical interaction between DNMT3a and PLK4 exists. HEK293T cells were lysed and a 
co-immunoprecipitation was performed with an anti-PLK4 antibody (cell signalling). Western blot 
analysis was then conducted and the membrane was probed with an anti-DNMT3a antibody (Santa-Cruz). 
DNMT3a was shown to be present in the endogenous PLK4 pull-down (Figure 4b). 
After the positive results from the co-IP, a protein pattern search was employed to find possible 
phosphorylation sites on DNMT3a. PLK4 binding motifs identified by 3 unique groups composed of 
Leung et al. (2007), Johnson et al. (2007), and Silibourne et al. (2010) were used on the amino acid 
sequence of DNMT3a (Table 1). 2 sites on DNMT3a were found using the Leung sequence, 0 were found 
using the Johnson sequence and 5 were found using the Silibourne sequence. Of the 5 sites found in the 
Sillibourne motif, 2 overlapped with the Leung motif, suggesting that serine 714 and serine 786 are 
potential sites of PLK4 phosphorylation (Figure 4a).  
Subsequently, to determine if DNMT3a is a direct substrate of PLK4, an in vitro kinase assay was 
performed. Bacterially expressed GST-DNMT3a was purified and incubated with immunoprecipitated 
Flag-PLK4 in a kinase buffer with ATP for 30 minutes. Kinase-dead and kinase-active mutants of PLK4 
were used as controls for assessing phosphorylation status of DNMT3a. However, there were no signs of 









Table 1: Phosphorylation Motif Sequences of PLK4. 
Three different groups derived PLK4 phosphorylation motifs independently. These motifs were applied 
on the amino acid sequence of DNMT3a to find possible phosphorylation sites. Each column represents 
favourable amino acid residues in relation to the serine/threonine phosphorylation site at position 0. X 



















Figure 4: DNMT3a is not a PLK4 substrate 
(A) Positive results of PLK4 phosphorylation motif search for amino acid sequence of DNMT3a using a 
protein pattern search provided by gene infinity. Highlighted sequences display similar serine 
phosphorylation sites found by separate motifs. (B) Endogenous co-immunoprecipitation of PLK4 and 
DNMT3a in HEK293T cells. (C) Kinase assays were performed to determine if PLK4 can phosphorylate 
DNMT3a. HEK293T cells were transiently transfected with Flag-Empty and Flag-tagged PLK4 
constructs, including wild-type (PLK), kinase active (KA, T170D), and kinase dead (KD, K41M) 
mutants. Constructs were immunoprecipitated with anti-FLAG antibody (Sigma) and incubated with 
bacterially expressed GST-DNMT3a in the presence of [ɣ-32P]. The assay was visualized by 
autoradiography (top image). Immuno-blots show loading of Flag-PLK4 constructs and purified GST-










Localization of DNA-Methyltransferase proteins in response to Centrinone-B 
Due to the physical interaction found between DNMT3a and PLK4 in the co-IP, it was of interest 
to further examine how PLK4 may indirectly affect methylation by examining the localization of DNA-
methyltransferase proteins in response to PLK4 inhibition. Centrinone-B is a potent PLK4 inhibitor that 
can disrupt centriole assembly by binding to the kinase domain of PLK4 and preventing phosphorylation 
of bound substrates. NIH/3T3 cells grown on glass slides were treated with 300nM of centrinone-B or 
DMSO (as a vehicle control). Cells were fixed with 3.7% PFA and incubated with DNMT1 (Cell-
Signalling), DNMT3a (Sigma-Aldrich), and DNMT3b (Santa-Cruz) antibody overnight and observed 
under immunofluorescence to visualize protein distribution. DNMT3a protein normally localizes to the 
nucleus as shown in the control samples. However, with centrinone-B treatment, the localization of 
DNMT3a changes dramatically to a perinuclear pattern (Figure 5a). The same perinuclear pattern can be 
seen with DNMT3b in centrinone-B treated samples but not with DNMT1 (Figure 5b,c).  
Due to the localization changes, it was important to examine if overall protein levels had been 
disrupted. To determine if DNA-methyltransferase protein levels changed under centrinone-B treatment 
the lysates from treated cells were extracted and Western blot analysis was performed. The blot was 
probed for DNMT3a, DNMT3b, DNMT1, and GAPDH was used as a loading control. Protein levels of 
the DNA-methyltransferases remained constant under centrinone-B despite the changes seen in 


















Figure 5: Centrinone-B affects localization of DNA-methyltransferase proteins 
The localization of DNMT3a, DNMT3b and DNMT1 was examined in NIH/3T3 cells treated with 
300nM of centrinone-B. DMSO was used as a vehicle control and DAPI (Hoechst 33342) was used to 
stain the nucleus. (A) Distribution of DNMT3a is dispersed throughout the nucleus but changes to a 
perinuclear localization with centrinone-B treatment. (B) Distribution of DNMT3b shows the same 
perinuclear staining as DNMT3a with centrinone-B. (C) Localization of DNMT1 is unaffected by 
centrinone-B. (D) Whole cell lysates (20ug) of centrinone-B treated cells were immunoblotted and probed 










Localization of DNA-Methyltransferase proteins in response to shRNA-PLK4  
The perinuclear localization of DNMT3a/b under centrinone-B treatment was overall unexpected 
and it was of interest to try and confirm whether this was related to PLK4 levels. It was hypothesized that 
PLK4 inhibition through shRNA knockdown might incur the same result. Thus, NIH/3T3 cells were 
transfected with an shRNA plasmid (shPLK4 or shSCR) and stained with DNMT3a and DNMT3b 
antibody to be monitored under immunofluorescence. The perinuclear localization of both DNMT3a and 
DNMT3b was observed in shPLK4-transfected cells but not in the shSCR control (Figure 6a).  
Densitometry was performed on 20ug of transfected cell lysates to determine PLK4 knockdown 
efficiency. GAPDH was used as a loading control and knockdown of PLK4 was calculated to be 56% 
(Figure 6b). 
 
Localization of DNA-Methyltransferase proteins in PLK4+/- MEFs 
Acute inhibition of PLK4 in NIH/3T3 cells provoked a localization change in DNMT3a/b. To 
further elucidate the effects of PLK4 on the localization of these proteins the heterozygous mouse model 
was investigated. PLK4 haploinsufficiency has been known to cause improper mitotic division and 
centrosomal imbalances, which may have caused of disruption of DNMT3a/b localization. To determine 
if the perinuclear localization of DNMT3a/b was due to PLK4 haploinsufficiency, wild-type and 
heterozygous PLK4 MEFs were observed under immunofluorescence. There were no signs of perinuclear 

















Figure 6: Knockdown of PLK4 affects localization of DNMT3a and DNMT3b 
The localization of DNMT3a and DNMT3b was examined in NIH/3T3 cells transiently transfected with 
an shPLK4 plasmid (MISSION shRNA, Sigma). A scrambled shRNA plasmid was used as a negative 
control (shSCR) and DAPI (Hoechst 33342) was used to stain the nucleus. (A) Distribution of DNMT3a 
and DNMT3b develop a perinuclear localization with PLK4 knockdown. (B) Immunoblot of whole-cell 
lysates (20ug) from shPLK4 transfected cells. Changes in PLK4 expression were quantified using 




















Figure 7: PLK4 haploinsufficiency does not affect localization of DNMT3a and DNMT3b 
The localization of DNMT3a and DNMT3b was examined in PLK4 heterozygous and wildtype murine 
embryonic fibroblasts (MEFs). Both proteins displayed normal phenotypes and their distribution was 

















Centrinone-B cell cycle profiles 
PLK4 inhibition has many serious effects on a population of cells such as delayed mitotic 
progression and increased genome ploidy [42,52]. To establish whether the perinuclear staining of 
DNMT3a was due to a cell cycle block, it was of interest to determine the cell cycle profile of centrinone-
b treated cells. Treated cellular pellets were fixed in 80% ethanol and stained with propidium iodide 
overnight. Untreated and vehicle controls have similar cell cycle profiles while  
centrinone-B treated cells displayed a large proportion of cells in one peak at the G2/M stage indicating a 
mitotic block (Figure 8a).  
Nocodazole is a mitotic inhibitor that disrupts polymerization of microtubules during mitosis and 
it produces a similar cell cycle profile to centrinone-B treated cells (Figure 7a). Because of the similar 
cellular effects of centrinone-B and nocodazole, it was important to investigate whether DNMT3a would 
have the same localization patterns under nocodazole as it did with centrinone-B. NIH/3T3 cells treated 
with nocodazole (Cell-signalling) and stained with an anti-DNMT3a antibody were monitored under 
immunofluorescence. There were no signs of perinuclear localization of DNMT3a after nocodazole 




















Figure 8: Nocodazole does not affect localization of DNMT3a 
Cell cycle profiles of NIH/3T3 cells were obtained by flow cytometry. Cell samples were stained with 
propidium iodide to quantify DNA. An untreated sample was used to set up forward scatter, side scatter, 
and doublet discrimination for the subsequent samples. (A) Untreated and DMSO samples displayed 
regular cell cycle profiles with one peak at G1/G0 and a second peak at G2/M. Centrinone-B and 
nocodazole treated samples displayed one large peak at G2/M. (B) Localization of DNMT3a was 











Centrinone-B affects global methylation in NIH-3T3 Cells 
After determining that PLK4 inhibition caused disrupted localization of DNA-methyltransferase 
proteins, it was necessary to investigate PLK4’s impact on DNA methylation. A global DNA methylation 
assay was performed to assess the effects of centrinone-B. DNA was extracted from plated cells that were 
treated with centrinone-B, DMSO, or nocodazole by phenol/chloroform extraction. A methylation assay 
kit from epigentek was used to determine global methylation status of treated cells. The kit was followed 
as instructed by using 100ng of DNA per sample. Global methylation levels were compared relative to an 
untreated negative control sample. Global DNA methylation was overall decreased in centrinone-b treated 
samples when compared to the untreated or DMSO samples. Nocodazole treatments were utilized as a 
cell cycle control, the DNA methylation level of these samples were similar to the negative control 
samples (Figure 9a). A student’s t-test revealed no significant differences across sample means. 
Due to the loss of global methylation levels after centrinone-b treatment, it was of interest to 
perform a rescue experiment. An inhibitor-resistant PLK4 mutant (G95L) has been shown to antagonize 
the effects of centrinone-b on centriole duplication. Hence, the PLK4 mutant (Flag-G95L) was transiently 
transfected in NIH/3T3 cells before centrinone-B treatment and observed under immunofluorescence. 
Cells stained for DNMT3a were counted to assess the proportion of perinuclear stained nuclei in response 
to PLK4 transfection. Wild-type PLK4 (Flag-PLK4) was used as a control. The overall proportion of 
perinuclear stained cells with centrinone-B was determined to be 26%. Flag-G95L transfected cells 
displayed a small decrease in the proportion of perinuclear stained cells. Cells transfected with Flag-
PLK4 had a similar percentage of perinuclear cells to samples with just centrinone-B treatment (Figure 
9b). 
Because of the observed decrease in perinuclear stained cells with Flag-IR, a global methylation assay 
was performed with similar cell treatments. Cells treated with centrinone-B show a similar decrease in 
methylation levels from previous experiments. Flag-PLK4 and Flag-G95L transfected cells both 










Figure 9: Analysis of Global methylation levels in NIH/3T3 cells 
(A) An ELISA-based global methylation assay was performed for the genomic DNA of NIH/3T3 cells 
treated with DMSO, centrinone-B and nocodazole. Histograms are representative of three independent 
experiments and normalized to the respective untreated samples. Error bars represent one standard 
deviation of the mean. (B) Perinuclear stained cells were counted in response to PLK4 transfection and 
centrinone-B treatment. The proportion of perinuclear stained cells were quantified by counting >200 
cells. Error bars represent the standard deviation from three independent experiments. Immunoblot of 
whole-cell lysates of transfected NIH/3T3 cells display presence of Flag-PLK4 and Flag-G95L. (C) A 
global methylation assay was performed to determine global methylation levels of NIH/3T3 cells 
transfected with Flag-IR and treated with centrinone-B. Histograms are representative of three 
independent experiments and normalized to the respective untreated samples. Error bars represent one 






























DNMT3a is not a substrate of PLK4 
Protein kinases are remarkable in that they can be involved in many different sub-cellular 
pathways due to the sheer number of possible phosphorylatable substrates within the cell at any given 
time. PLK4, thus far, is mainly noted for its roles in cell cycle regulation and centriole duplication. Ward 
and Hudson have alluded to PLK4 having a potential role in epigenetic regulation by affecting the protein 
levels of DNA-methyltransferase proteins [47]. Understanding PLK4’s involvement in this pathway may 
be useful in diagnosing and treating epigenetic related diseases. Therefore, the goal of this study was to 
determine the role of PLK4 in epigenetic regulation.  
As an initial step we examined whether DNMT3a could be a direct substrate of PLK4. By 
utilizing co-IP experiments and in-vitro kinase assays we determined that there exists a physical 
interaction between the two proteins but did not identify a direct kinase interaction (Figure 4b,c). While 
we could not detect the phosphorylation of DNMT3a by PLK4 under these specific conditions, the co-IP 
results imply that both proteins could engage with a larger protein complex that may be composed of 
overlapping binding partners. Intriguingly, both proteins have been reported to physically interact with 
p53 in vitro [45,111]. The functional significance of the PLK4 and p53 interaction is not well understood 
but the binding of DNMT3 to p53 was shown to be inhibitory and able to repress p53-mediated 
transactivation of the p21 gene. This proposed complex involving PLK4, DNMT3a, p53 and other cell 
cycle regulatory proteins may be a major spotlight for future research. 
By using the PLK4 phosphorylation consensus sequences, we found 2 possible phosphorylation 
sites for DNMT3a which were S714 and S786 (Figure 4a). Interestingly, S714 mutations have been 
reported to be a recurrent DNMT3a mutation involved in the development of myelodysplastic syndromes 
[112]. This is a common missense mutation that turns serine into a non-phosphorylatable cysteine amino 




finding may direct future studies to utilize other kinase assay methods. As we know, phosphorylation and 
dephosphorylation are vital signals that may alter the protein’s stability, activity, localization and affinity 
for other substrates. If this interaction exists, this may link PLK4 directly to an epigenetic mechanism that 
is related to disease progression. This is a promising finding because our lab has reported that PLK4 
protein levels are commonly disrupted in MDS and other blood related malignancies and DNMT3a is 
known to be dysregulated in the same neoplasms [112]. 
 
Centrinone-B affects DNMT3a and DNMT3b localization 
Most biological studies of gene function involve utilizing knockout and knockdown methods or 
small molecule inhibition to study phenotypic effects. Luckily for PLK4, much has been done in regards 
to knockout mouse models and functional assays. There are many selective PLK4 inhibitors that exist and 
have been employed in biological assays, some of which are in phase 1 clinical trials for the treatment of 
advanced solid tumors [113, 114]. Of the drugs that exist, centrinone-B has recently come into the 
spotlight as a potent and selective inhibitor for PLK4. Centrinone-B has been experimentally shown to 
directly target and inhibit PLK4 through its kinase domain and prevent centriole assembly in cultured 
cells [110]. Due to the specificity and availability of centrinone-B we decided to utilize it as a small 
molecule inhibitor to target PLK4 for epigenetic related experiments. 
We examined if PLK4 inhibition could affect the localization of DNA-methyltransferase proteins 
and their overall abundance. To our surprise, we found that Centrinone-B treatments on mouse fibroblast 
cells could change the localization of DNMT3a and DNMT3b, two de-novo methyltransferases, without 
changing the overall levels of these proteins. Interestingly, the localization of DNMT1, the maintenance 
methyltransferase, remained unaffected by centrinone-B (Figure 5). This may be due to DNMT3a and 3b 
being similar in regards to protein structure, size, and amino acid sequence. DNMT1 is overall much 
larger than DNMT3a/b and has a larger number of defined, functional protein domains [115]. By 




There are numerous studies elucidating the functions of DNMT3a and DNMT3b in hematopoiesis and 
embryonic lethality is an outcome of DNMT3a/DNMT3b double knockouts in mice due to a 
differentiation block [116].  
Interestingly, the overall protein level of PLK4 also affects the localization of the de-novo 
methyltransferases. With the ShRNA PLK4 construct, we observed that knockdown could cause the 
perinuclear localization of DNMT3a and DNMT3b (Figure 6). Centrinone-B does not affect the levels of 
PLK4 but rather its kinase ability in vivo. Our findings here indicate that because the knockdown caused a 
similar effect, it must be a PLK4 specific mechanism that is causing the dysregulated localization 
patterns. This relationship is alluring because our lab has shown that the PLK4 gene promoter is 
commonly methylated in hematological cancer tissues and hematological cancer cell lines. Also, the 
PLK4 promoter increasingly becomes methylated in blood neoplastic cell lines under hypoxia which 
means that lower levels of PLK4 protein could be induced under DNA damage and lead to changes in 
DNA methylation [109]. This dysregulation of DNMT3a and DNMT3b localization could be an acute 
effect that may occur in response to cellular stresses where PLK4 becomes inhibited or downregulated. 
The hypothesis that the perinuclear localization of the de-novo methylases is a short-term effect is 
supported by our own findings in PLK4+/- MEFS. When observed under immunofluorescence, there were 
no signs of disrupted localization of DNMT3a and DNMT3b (Figure 7). This signifies that the long-term 
haploinsufficient effects seen in PLK4 mouse models such as increased apoptosis or genomic instability 
was not the cause of the perinuclear localization. In fact, it only occurred under short time spans such as 
transient transfections with ShRNA or Centrinone-B treatment. Future studies could further investigate 
this relationship by finding other ways to acutely affect PLK4 levels such as using other well known 
PLK4 inhibitors or using hypoxia treatment [109].  
PLK4 has numerous roles in the cell cycle and inhibition causes drastic changes to the cellular 
environment. Most findings conclude that PLK4 inhibition and knockdown cause a mitotic block due to 
the incomplete duplication of centrosomes and causes an increase in the proportion of cells in the G2/M 




by a cell cycle block. Our observations of Centrione-B treatments on the cell cycle agree with the overall 
literature; Centrione-B increases the proportion of cells in the G2/M phase (Figure 8). We sought to 
examine a similar population of cells using a different treatment to investigate whether the subcellular 
localization of DNMT3a/b is cell cycle dependent. Nocodazole is a microtubule inhibitor that has been 
used in many studies to effectively arrest cells in mitosis. It causes a similar cell cycle profile to 
centrione-B treated cells, however, we did not observe a perinuclear pattern of DNMT3a localization in 
cells with nocodazole treatment (Figure 8).  
It is important to mention that while nocodazole produces a similar population of cells it does not 
inhibit the cell cycle in the same way. Centrinone-B causes centriole depletion causing cells to arrest in 
G2 delaying entry into mitosis [110]. Nocodazole inhibits the polymerization of microtubules while in 
mitosis so that cells cannot properly divide. Nocodazole treated cells enter mitosis while centrinone-b 
treated cells do not, causing a similar cell cycle profile in regards to DNA content but a different state in 
regards to cell cycle phase. This differentiation is important because different states of the cell cycle will 
have different gene products activated during that time. At present, our results only suggest that DNA 
content does not affect the localization of DNMT3a.  
 
Centrinone-B affects global DNA methylation  
The subcellular localization of proteins is one mechanism by which proteins are regulated. For 
example, most proteins are created outside of the cell by ribosomes in the endoplasmic reticulum and 
need to be transported to the locations where they function. Many proteins that are known to work mainly 
in the nucleus must be transported inside through nuclear localization signals (NLS), which are 
programmed into their amino acid sequence. Studies that have mutated these NLS sites have found that 
without particular sequences, these proteins cannot enter the nucleus and they observe similar phenotypes 
to a full gene knockout [49,50]. Thus, the localization of a protein is important in its own functional 




Due to the perceived localization changes to DNMT3a and DNMT3b found in response to 
centrinone-B, we investigated if this could affect global DNA methylation. Using an ELIZA-based assay, 
we determined that centrinone-B treatment decreased global DNA methylation within 3T3 cells (Figure 
9a). In support of our other findings, this decrease was likely caused by the inhibited catalytic function of 
the de-novo methyltransferases due to dysregulated subcellular localization. The overall methylation 
changes were compared to an untreated control and the global methylation decrease was observed to be 
~27%. While the relative change can be seen as a nominal amount, it may be important to note that many 
epigenetic studies have concluded that DNMT1, the maintenance methyltransferase, is the most important 
in regulating large changes in global DNA methylation. Individual knockouts of DNMT proteins reveal 
no large change in global methylation levels, however, double knockouts of DNMT1 along with 
DNMT3a or DNMT3b have been shown to produce drastic differences in methylation [119,120,121]. We 
observed that DNMT1 was unaffected by centrinone-B which may explain why we did not observe a 
drastic change in global methylation levels and also why we did not find any significant difference using 
a student’s t-test. Furthermore, our nocodazole control did not show a decrease in global methylation 
indicating that the abundance of DNA did not change the proportion of methylated DNA. This was 
expected as nocodazole did not change the localization patterns of DNMT3a/b as we found in centrinone-
B treated cells. 
The first group to investigate the effects of centrione-B on centriole duplication also found that a 
mutated form of PLK4 could rescue the effects [110]. The inhibitor resistant PLK4 (PLK4-G95L) has a 
mutation in the kinase domain that hindered centrinone-B binding. We used this same PLK4 mutant to 
see if it could rescue the effects of decreased DNA methylation. By transiently transfecting PLK4-G95L 
we observed that a lower proportion of cells displayed the perinuclear phenotype when treated with 
centrinone-B (Figure 9b). Furthermore, when we measured global DNA methylation, we saw a trending 
increase in global methylation (Figure 9c). Wild-type PLK4 was used as a control and we did not see a 




Our results suggest that PLK4 plays a role in regulating global DNA methylation levels by governing the 
localization of DNMT3a and DNMT3b. 
A student’s t-test revealed no significant difference between samples due to high variance. This is 
a common problem when working with a population of treated cells; not all cells will be expressing our 
PLK4 plasmids due to transfection efficiencies. Replicative studies using a stable cell line expressing 
these plasmids should be considered for future experiments. We would still expect a similar outcome 
using a stable cell line, but with more pronounced differences when we measure DNA methylation.  
 
Concluding Remarks 
Our results suggest interesting roles for PLK4 in epigenetic regulation. Firstly, PLK4 inhibition 
and protein levels can regulate the localization of de-novo methyltransferases, which may indicate that 
PLK4 is needed for cell differentiation. PLK4-/- mice are embryonic lethal at day 7.5 and morpholino 
studies in xenopus show that PLK4 is necessary for proper somite formation [122,123]. These phenotypes 
have been alluded to microtubule and cell polarity disruptions but our experiments show that PLK4-
mediated epigenetic regulation may play a supporting role. Much of embryogenesis is controlled by large 
epigenetic reprogramming events through DNA methylation and the DNMT family members are crucial 
in this regard [124]. X-chromosome inactivation is one such event that completes by E6.5 in mammalian 
embryos and is carried out specifically through the de-novo methyltransferases [125]. PLK4-/- embryos 
may lack coordination of DNMTs to undergo this event and thus abort due to differentiation defects. 
Additionally, other groups have determined that DNMT3a is especially important for proper somite and 
neural-tube formation in zebrafish and WT mouse embryos; structures that are morphologically absent in 
PLK4-/- embryos [126,127,128]. We show that PLK4 inhibition can affect global DNA methylation by 





Interestingly, our lab has reported that hematological cancerous tissues and cell lines are 
subjected to PLK4 promoter methylation, which directly affects PLK4 protein levels [109]. PLK4 
promoter methylation could also be induced by hypoxia, which may be an early step for cancer 
development. We observed that PLK4 levels directly affect DNMT3a/3b localization that may further 
increase potential for neoplastic development due to disrupted epigenetic pathways. Furthermore, we 
could not detect direct phosphorylation of DNMT3a by PLK4 with our methods but hypothesize that they 
could be involved in a larger cell cycle regulating protein complex that includes tumor suppressor p53. 
Overall, we examined the effects of PLK4 inhibition on DNA methylation. We show that 
Centrinone-B, a potent PLK4 inhibitor, can disrupt the localization of DNMT3a and DNMT3b and cause 
a global loss of DNA methylation in mouse fibroblast cells without modifying protein levels. 
Dysregulated localization of DNMT3a/3b can also be achieved with ShRNA knockdown of PLK4 
indicating that it must be a PLK4-specific mechanism. Our results highlight a potential mechanism for 
PLK4-mediated epigenetic regulation that may be important in tissue differentiation. PLK4 mainly 
regulates centrosomes but could also act in multiple pathways during development and embryogenesis 
when tissue differentiation is crucial to the formation of highly complex structures. Understanding 




Our results indicate that DNMT3a is not phosphorylated by PLK4 in our specific in-vitro 
conditions. The potential phosphorylation sites found for DNMT3a in the motif search are still 
compelling because both proteins are involved in the progression of blood neoplasms [104,112]. Due to 
serine 714 in DNMT3a being a recurring mutated amino acid linked to MDS we think that other known in 
vivo kinase assay methods could be employed to determine if this interaction exists. There is also the 




localization of DNMT3a; this could involve p53. Whether or not DNMT3a is a PLK4 substrate, it would 
be interesting to further elucidate their interactions with p53 because it is a common binding partner for 
both proteins. Future experiments could consist of co-IP or mass spectrometry analysis of PLK4 pull-
down samples to determine the presence of both DNMT3a and p53 in tandem. Furthermore, since PLK4 
and p53 activity can be induced by DNA damage, functional assays may investigate how DNMT3a might 
be involved in the same pathways that may include: localization, substrate binding, and catalytic activity. 
Experiments to assess overexpression effects of each protein during embryogenesis or DNA damage 
should also be considered.  
The results using nocodazole as a cell cycle inhibitor should be more refined. Nocodazole does 
not inhibit the cell cycle the same way PLK4 does. In this regard, I would suggest using a CDK1 inhibitor 
or an additional but different PLK4 inhibitor to arrest cells in G2. These treatments would be used to 
further assess DNMT3a/b localization and global methylation levels.  
Further experiments that revolve around PLK4 and epigenetic regulation should also consider its 
interaction with PRMT5, a histone methyltransferase. Our lab has identified PRMT5 as a PLK4 substrate 
that localizes to the centrosomes and is dysregulated in PLK4+/-  MEFS [129]. Experiments involving 
PLK4 inhibition or knockdown with PRMT5 may further clarify PLK4’s role in epigenetic regulation 
because histone-methyltransferases frequently associate with DNA-methyltransferases in larger protein 
complexes [130]. PLK4 could possibly regulate localization and function of DNMT3a through the 


















Figure 10: Model for PLK4-mediated regulation of DNA methylation through PRMT5 
PRMT5 is a PLK4 substrate that also localizes to the centrosome. After phosphorylation by PLK4, 
PRMT5 could localize to its histone targets (H4R3) and methylate the arginine tails. Methylation of 
histones can also promote the recruitment of DNMT3a to further methylate nearby CpG sites. Catalytic 
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Appendix A: BioID Project 
Phosphorylation is the main post-translational modification that is involved in signal transduction 
[1]. As a result, kinases and phosphatases are an important area of research to investigate inner cellular 
mechanisms [2]. By understanding these proteins and their substrates we can hypothesize how they 
function simultaneously or sequentially to affect the overall cellular architecture. Finding these substrates 
for kinases is an overall difficult task because of the sheer number of possible binding partners, however, 
many groups have identified that cellular localization and proximity can be indicative of potential 
substrate binding [3].  
The BioID system is one technique that has been used to determine the interacting partners of 
proteins by employing a biotin ligase (BirA) fusion-protein [4]. In the presence of biotin, the BirA fusion-
protein will biotinylate proximal proteins which can then be identified using LC/MS. This system has 
been used in mammalian cells to confirm PLK4 interacting with centrosomal proteins CEP152 and 
CEP192 [5]. We developed a BioID-PLK4 plasmid to be expressed in xenopus laevis to confirm 
homologous gene interactions and to potentially find new binding partners. The plasmid was successfully 
expressed in HEK293T cells (Figure A1, A2). 
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Appendix B: Plasmid Maps 
 
Figure A1: Myc-BIOID-PLK4 Mammalian 
Depiction of a mammalian plasmid map containing full-length human PLK4 cDNA. Aaron Hagazi 
created this plasmid. Fully sequencing the plasmid revealed missense mutations at amino acid positions 
637 and 652 in PLK4. These mutations were fixed using the primers found in table B1. The CMV 
promoter is depicted in green, the Myc-BirA fusion tag is depicted in red and the PLK4 cDNA is depicted 
in blue. The plasmid was successfully transfected and expressed in HEK293T as shown in the blot. Myc-










Figure A2: Myc-BIOID-PLK4 Xenopus 
Depiction of a Xenopus plasmid map containing full-length human PLK4 cDNA. This plasmid was 
created by using restriction enzymes Nru1 and Sma1 on the previous mammalian plasmid and blunt-end 
ligating the product into a new xenopus backbone. The CMV promoter is depicted in green, the Myc-
BirA fusion tag is depicted in red and the PLK4 cDNA is depicted in blue. This plasmid contains I-SceI 
mega-nuclease sites for the purposes of genomic integration into fertilized xenopus eggs. The plasmid 
was successfully transfected and expressed in HEK293T as shown in the blot and Myc-PRMT5 was used 














637 Mutation 5'-agaatatgtgaaagaagttcttcagatatctagtgatggaaatacga-3' sense 
5'-tcgtatttccatcactagatatctgaagaacttctttcacatattct-3' anti-sense 
652 Mutation 5'-gatggaaatacgatcactatttattatccaaatggtggtagaggtttt-3' sense 
5'-aaaacctctaccaccatttggataataaatagtgatcgtatttccatc-3' anti-sense 
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